A Phase 2 interventional study of Famotidine and Levocetirizine in Functional Gastrointestinal Disorders, sponsored by Buddhist Tzu Chi General Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Buddhist Tzu Chi General Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Gastrointestinal Diseases with a site in Taiwan — 5 open to participants now, 6 under way, 2 of them phase 3. Gastrointestinal Diseases · Taiwan.
Among the 15 studies in Gastrointestinal Diseases with a site in Taiwan, this one is the 11th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2025, is one of 2 in phase 2, and was the 14th registered.
549 studies on the registry are indexed under Gastrointestinal Diseases; 102 are open to participants now.
Browse Gastrointestinal Diseases studies →5 of the 15 studies in Gastrointestinal Diseases with a site in Taiwan are open now. Recruiting first, the newest first:
Pfizer · Sites in Taiwan, United States, Argentina and 17 more countries
Ages 18+
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 7–30 · Healthy volunteers
Taipei Veterans General Hospital, Taiwan · Sites in Taiwan
Ages 20–85
Turning Point Therapeutics, Inc. · Sites in Taiwan, United States, Australia and 16 more countries
Ages 12+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 66 Gastrointestinal Diseases studies recruiting now, 30 (45%) set no upper age limit and 23 (35%) stop at 75 or younger; 19 take children under 18; 21 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 5
First in 2010; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 45 is below the median of 80 across 388 interventional studies indexed under Gastrointestinal Diseases.
Median enrollment 102 across the 14 interventional studies, 134 across the 1 observational. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 15 have an industry lead sponsor. The 9 most frequent:
Buddhist Tzu Chi General Hospital is the lead sponsor of 88 studies on the registry; 20 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Buddhist Tzu Chi General Hospital has 5 studies filed under Gastrointestinal Diseases — fewer than ten, so there is no comparison to draw.
2 of the studies in Gastrointestinal Diseases with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07857941Buddhist Tzu Chi General HospitalExploring Novel Therapeutic Approaches for Disorders of Gut-Liver-Brain Interaction-H1/H2 | 2026-12-31 |
| NCT06290258Chang Gung Memorial HospitalFecal Microbiota Transplantation for Patients With Autism Spectrum Disorder. | 2027-07-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Gastrointestinal Diseases with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Functional dyspepsia (FD) is associated with inflammatory responses caused by the release of histamine from eosinophils and mast cells, leading to increased intestinal mucosal permeability, which is a key pathogenic mechanism.
Meta-analyses have shown that H2 antihistamine drugs are as effective as proton pump inhibitors in treating FD, while H1 antihistamines achieve an efficacy rate of up to 79%. However, there is no research comparing the effects and pathological changes of combined H1/H2 antagonists versus single H1 antagonists in the treatment of functional dyspepsia.
Recent studies have shown that fatty liver disease and irritable bowel syndrome (IBS) share common comorbid factors, including obesity, gut microbiota, dietary factors, and immune-mediated causes. This has raised interest in whether these two conditions co-exist in patient populations. Moreover, the prevalence of IBS is higher in patients with fatty liver disease compared to global prevalence rates. A recent study found that up to 55.6% of patients with fatty liver have IBS, and it further suggests that patients with both IBS and fatty liver experience a lower quality of life and more severe physical and psychological symptoms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Famotidine 20mg/tab This product is used for the treatment of peptic ulcers and gastroesophageal reflux disease (GERD). It competitively inhibits histamine at the H2 receptors on gastric parietal cells, thereby reducing gastric acid secretion (Ministry of Health and Welfare Drug License No. 041352). Levocetirizine 5mg/tab This is an antihistamine used to relieve various symptoms of allergies. Levocetirizine is an antihistamine that selectively competes with histamine at the H1 receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory system (Ministry of Health and Welfare Drug License No. 023792).
Levocetirizine 5mg/tab This is an antihistamine used to relieve various symptoms of allergies. Levocetirizine is an antihistamine that selectively competes with histamine at the H1 receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory system (Ministry of Health and Welfare Drug License No. 023792). "Fuyuan" Gasmin Tablets 40mg/tab This product appears as a round, white tablet. It works in the gastrointestinal tract by reducing the surface tension of gas bubbles, causing the bubbles attached to the gastrointestinal mucosa to rupture due to the change in tension. This facilitates the expulsion of gas from the body through belching or flatulence. (Taiwan FDA Drug License No. 000415).
"Fuyuan" Gasmin Tablets 40mg/tab This product appears as a round, white tablet. It works in the gastrointestinal tract by reducing the surface tension of gas bubbles, causing the bubbles attached to the gastrointestinal mucosa to rupture due to the change in tension. This facilitates the expulsion of gas from the body through belching or flatulence. (Taiwan FDA Drug License No. 000415).
Drug: Fuyuan Gasmin
20mg twice daily
5mg once before bed
40mg/tab once before bed
40mg/tab twice daily
Change from Baseline on the Functional Dyspepsia Scale(FD) at 84 days
Possible scores range from 0 (Very slightly) to 6 (Very serious) 0=Very slightly 1=Slight 2=A little slightly 3=About medium 4=A bit serious 5=Severe 6=Very serious Change = (day 84 Score - Baseline Score).
Time frame: Baseline and day 84
Change from Baseline in Pain on the Gastrointestinal symptom rating scale (GSRS) at 84 days
Possible scores range from 1 (No pain) to 7 (very serious) 1=No pain 2=Very minor 3=Mild 4=Moderate 5=Moderate to severe 6= severe 7=very serious Change = (day 84 Score - Baseline Score).
Time frame: Baseline and day 84
Change from Baseline on the Pittsburgh sleep quality index (PSQI) at 84 days
Possible scores range from 0 (Never) to 3 (Occurs three times a week times or more) 0=Never 1=Less than once a week 2=Occurs once or twice a week 3=Occurs three times a week times or more Change = (day 84 Score - Baseline Score).
Time frame: Baseline and day 84
Change from Baseline on the Taiwanese Depression Scale (TDQ) at 84 days
Possible scores range from 0 (Never) to 3 (Always) 0=Never 1=Sometimes 2=Often 3=Always Change = (day 84 Score - Baseline Score).
Time frame: Baseline and day 84
Change from Baseline on the State-Trait Anxiety Inventory (STAI) at 84 days
Possible scores range from 1 (Never) to 4 (Always) 1=Never 2=Sometimes 3=Often 4=Always Change = (day 84 Score - Baseline Score).
Time frame: Baseline and day 84
Change from Baseline on the Perceived Stress Scale(PSS-10) at 84 days
Possible scores range from 0 (Never) to 4 (Always) 0=Never 1=Rarely 2=Sometimes 3=Often 4=Always Change = (day 84 Score - Baseline Score).
Time frame: Baseline and day 84
Change from Baseline on the Visceral Sensitivity Index (VSI) at 84 days
Possible scores range from 0 (Strongly disagree) to 5 (Strongly agree) 0=Strongly agree 1=Moderately agree 2=Mildly agree 3=Mildly disagree 4 =Moderately disagree 5=Strongly disagree Change = (day 84 Score - Baseline Score).
Time frame: Baseline and day 84
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 23 months after the start.
Of 23 phase 2 interventional studies under Gastrointestinal Diseases, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 46. This study's planned 23 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Buddhist Tzu Chi General Hospital